AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency ...

The drug had already failed in two phase 3 trials in 2012 – but Lilly pressed on with a third trial in mild Alzheimer’s after spotting a trend in the data suggesting an effect in a small group ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the approval of the drug on Thursday. Indiana-based pharmaceutical company Eli ...

The drug works by removing a form of plaque known as beta-amyloid in an Alzheimer’s patient’s brain. “This unique mechanism and antibody for clearing plaques, discovered at Lilly ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

A new report shows up to 7.2 million Americans aged 65 and older are living with Alzheimer’s disease, an increase of about 300,000 cases.

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key Alzheimer’s drug given the green light in Europe. Discover outperforming ...

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...

April 25 (Reuters) - Eli Lilly (LLY.N), opens new tab has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday. Last month ...